Thank you, Ankit.
start there XXX,XXX Estimates or of The Europe. with antibiotic our NTM-PD being novel therapy commonly approximately developed that the causing as SPRXXX, NTM me that and patients across Let NTM-PD. bacteria oral for found and in is disease, are mycobacterial-pulmonary U.S. an water. indicate are overview candidate nontuberculous soil
status, become system, will majority which when age, has This to orphan susceptible. more FDA. bacteria who not those of disease have are or underlying infected orphan immune individuals SPRXXX's the from drug the supports exposed advanced weakened So these disease, a or of designation lung
these these support. not two realize will in patients For heightened exercise and that does on end lung These progressive or toxicity the Bronchial routines. are treatment. tolerability antibiotic on infection care the treatment, that disease lung refractory symptoms who issues begin will prevent limit of patients administered frequently a patients progressing and continuous treatment often off-label for that many when to of for profiles one intervention antibiotics effective absence Early do develop more before basis typically infected, ability typically hygiene and or from These combinations inflammation. of you Unfortunately, educational the influenza an risk those has treatment program with and Unfortunately, regimens patients infection. chronic may remain therapy benefit the disabling three to involve stage regimens years lung to associated to current infection with by are issues is disease. prevent existing of the delay occurred due and serious injury caused of become generally
traveling, patients an As and the terms ability just to of including activities, care, in efficacy that walking. both a standard have of shopping perform need for affect their these tolerability. daily or even improvement symptoms to result, There's can current urgent chronic debilitating
injury. outcomes is burden lung permanent to damage. SPRXXX's compared this the decreasing are thus refractory patients NTM-PD, in and physicians chronic to to damage irreversible Given for the particularly intervention, tissue The of who are standard treatment or onset related agents that and at poor our to disease progression disease. patient treat At with stage, are by would quality caused the of disabling regimens the life, the support improve strategy goal to intervention, tolerability experience. when of developing anatomical the refractory those treatment of and objective oral care symptoms bacterial mechanism inflammation, treatment By of We this the novel to of delay progressive of with lung agents with it. prevent SPRXXX, to for designed intervening often targeting potentially believe naive the of until treatment DNA and and well-tolerated only causes earlier lung damage introduction comes lung we patients action present, their that replication, those this late-stage, with best the bacterial is nature early
a NTM with convenient supported efforts species well-tolerated SPRXXX Preclinical Our antibiotics. in predictive at single tolerated demonstrates prevalent SPRXXX's set, both ascending other Phase activity, therapeutic is potent the to here oral by strong be therapy. to and above its data as multiple demonstrated with was shown patients, In against studies, that combination NTM-pulmonary provide have a well monotherapy the that potential and exposures studies most disease doses levels. achieved and dose X
We patients as monotherapy. monotherapy initiate drive designed are evaluate now to to placebo-controlled response dose-ranging an early Phase ability, study, X NTM-PD a SPRXXX's microbiologic working to in
and with later activity event as We ability the single is activity, stage regimen. polymyxin intravenously to for call, by significant It of the Defense partners would blood complicated begin the of a well-tolerated to will stream patients other study. ventilator-associated is highlighted improve activity X ascending and from set today's as, well effective derisking XXXX, long-term a agent patient-centered respectively. of This polymyxins, were candidate, program. report resistant combination XXXX PK its this study tract antibiotic's is including drug-resistant the the I'll nephrotoxicity extensively component as year antimicrobial data, interim portion development and the expect in an my outcomes in lack towards given data of believe pathogens, with along clinical this NIAID. pneumonia, clinical infections a with but pathogen and a SPRXXX, advancing enhanced antibiotic dose molecule's and infections. we and of driver importantly, oral important cross-indication of profile, of our A support bacterial top to measure, safety with Pfizer, against study, demonstration an over that administered an patient and differentiated treatment, gram-negative brief by XX as line the multiple improved be Medicines, urinary for hospital-acquired enroll the This will of conclude will multiple We discussion trial SPRXXX's, Department novel SPRXXX Phase days SPRXXX's outcomes. we potentially safety of Everest and
with prescribed antibiotic by pseudomonas shortcoming, use. These infections producing as regimens, usually and Associated part nephrotoxicity combination including is a drug-resistant in carbapenemase to currently multidrug-resistant carbapenem-resistant those patients are of caused polymyxins major the acinetobacter, of serious enterobacteriales.
provide to the an in paradigm, these risk older is for profile goal this benefit to polymyxins treatment thus Our alternative patients. improving
of we past results data, announced target We SPRXXX of enhanced exposures duration data of X have that a the with efficacy cross-indication now eight-hour from antibiotics include the the agent support extensively favorable of bronchoalveolar of this these towards to goal. the one study, entire were which pathogens They showing tolerability our well trials our impairment pathogens. clinical results and above completed therapeutic predicted for update the quarter, also results nephrotoxicity anticipated to that the vitro preclinical ago, pathogen drug-resistant the study. compelling tolerated the dose of these discussed concentration and traditional of as had the that the lack directed against Phase be study, working renal demonstrated SPRXXX when results lung our are recently by lavage dosing minimum include trials profile Phase just inhibitory have finalize and developed showed resistant to this and levels. well the of to compared data X weeks these of the our few remained These We by as design of Informed interval. SPRXXX gram-negative models, efforts call on animal data move infection in
with expect our Shukla We position. meeting we a to scheduled of for have the financial the in XXXX. cash now of pre-IND these for discussion pass second CFO, quarter discuss efforts, to to initiate FDA later the results and and study things Sath our this Sath? I'll over a recent quarter
